IMR Press / RCM / Volume 23 / Issue 8 / DOI: 10.31083/j.rcm2308277
Open Access Review
Emerging Concepts on Infection of Novel Cardiac Implantable Devices
Show Less
1 Department of Precision Medicine, University of Campania ‘L. Vanvitelli’ Napoli, Italy and Unit of Infectious and Transplant Medicine, AORN Ospedali dei Colli-Monaldi Hospital, 80131 Napoli, Italy
*Correspondence: (Emanuele Durante-Mangoni)
Academic Editors: Michele Di Mauro and Jochen Wöhrle
Rev. Cardiovasc. Med. 2022, 23(8), 277;
Submitted: 12 May 2022 | Revised: 10 June 2022 | Accepted: 27 June 2022 | Published: 5 August 2022
Copyright: © 2022 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.

Novel cardiac devices, including the MitraClip system, occluder devices, leadless pacemakers, and subcutaneous implantable cardioverter defibrillators (S-ICD), are mostly used in the management of patients who are at high risk for surgery and/or developing infections. Several mechanisms render most of these devices resistant to infection, including avoiding long transvenous access and novel manufacturing material. Since subjects who use these devices already endure several comorbid conditions, uncommon cases of device-associated infection could result in serious complications and increased mortality. In this review, we aim to summarize the current state of evidence on the incidence, clinical presentation, management, and prognosis of new cardiac devices’ associated infection.

new cardiac device
infective endocarditis
occluder devices
cardiac contractility modulation
Fig. 1.
Back to top